Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout
Main findingResult — go to the resultHazard ratio 1.22 95% CI 1.05–1.41Authors' conclusion
In this large population-based cohort of gout patients, allopurinol was associated with an increased risk of composite CV events and all-cause mortality compared to benzbromarone.
Study context
- Population
- Patients with gout initiating urate-lowering therapy, Korean National Health Insurance claims data (2002–17)2,258 with composite cardiovascular (CV) event
- Participants
- 124,434 patients
- Exposure
- Allopurinol vs benzbromarone
- Allopurinoln = 103,695
- Benzbromaronen = 20,739reference
- Outcome
- Composite CV endpoint of MI, stroke/TIA, or coronary revascularization
- Follow-up
- Mean 1.16 years
Methodological detailspropensity-score matched (5:1), population-based
- Propensity-score matched (5:1)
- Population-based
Main finding
As reported in the abstract
Hazard ratio
1.22
95% CI 1.05–1.41
By group
Allopurinol
1.81 per 100 person-years
Benzbromarone
1.61 per 100 person-years
Allopurinol vs Benzbromarone
HR 1.22 (95% CI 1.05–1.41)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality | 1.66 (1.43–1.93) | |
| 0.512Hazard ratio (log scale) |
Original publication
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J. Published 11 September 2021. doi:10.
Summarised from the published abstract; every number is checked against it